主管单位:中华人民共和国
国家卫生健康委员会
主办单位:
总编辑:杨秋
编辑部主任:吴翔宇
邮发代号:80-528
定价:28.00元
全年:336.00元
Email:zgyy8888@163.com
电话(传真):010-64428528;
010-64456116(总编室)
英文作者:Liu Hongli Yu Yang
英文单位:The Second Department of Cardiac Surgery Beijing Anzhen Hospital Capital Medical University Beijing 100029 China
英文关键词:Coronarythrombus;Antiplatelet;Perioperativepriod;Bridgingtherapy
在心脏支架置入术后6个月内由于外科手术中断口服双联抗血小板治疗的患者有发生血栓事件的风险。考虑到术中止血与术后引流问题,临床实践中医师对停药与桥接的治疗决策有较大差异,此外,对于气管插管的患者,口服给药途径的抗血小板药物应用受限。该类患者中断抗血小板药物后,无保护的暴露时间越长,发生血栓事件的概率越高。静脉途径抗血小板药物半衰期短,是理想的桥接药物。本文就该类患者抗血小板药物治疗的应用总结阐述。
The discontinuation of dual antiplatelet therapy results in the risk of thrombotic events in patients undergoing surgical operation within 6 months after coronary stent implantation. Considering the surgical hemostasis and postoperative drainage, doctors have quite different antiplatelet therapy decisions on stopping and bridging in clinical practice. In addition, in patients with endotracheal intubation, the use of oral antiplatelet is limited. After discontinuation of antiplatelet drugs in these patients, the longer the unprotected exposure time, the higher probability of thrombosis events will be. Intravenous antiplatelet drugs are ideal bridging drugs because of the short half-life. This article summarizes the application of antiplatelet drug therapy in such patients.
copyright
地址:北京市朝阳区安贞路2号首都医科大学附属北京安贞医院北楼二层
电话:010-64456116 传真:010-64428528 邮编:100029 Email: zgyy8888@163.com
网址: 京ICP备2020043099号-3
当您在使用本网站投稿遇到困难时,请直接将稿件投送到编辑部邮箱zgyy8888@163.com。